ArticleBMC cancer2026
Distribution and rate of lymph node metastasis following neoadjuvant chemoimmunotherapy in non-small cell lung cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeoadjuvant chemoimmunotherapy (NCIT) has emerged as a standard care for resectable non-small cell lung cancer (NSCLC). However, the pattern of lymph node metastasis (LNM) following this treatment remains poorly characterized. This study aimed to elucidate the distribution and rate of LNM after NCIT.
methodsWe retrospectively analyzed 394 NSCLC patients who received NCIT followed by R0 resection at Shanghai Pulmonary Hospital between 2019 and 2022. Pathological data were evaluated to determine LNM distribution and rate, with subgroup analyses performed based on tumor location and histology. Multivariable logistic regression identified independent predictors of nodal downstaging. Kaplan-Meier analyses evaluated survival outcomes based on the extent of lymphadenectomy. Multivariable Cox proportional hazards regression models were performed to identify independent prognostic factors associated with disease-free survival (DFS) and overall survival (OS).
resultsAmong the 394 patients, predominant LNM stations were 13R (9.4%), 7 (9.4%), 13L (5.8%), 2R (5.6%), 4R (5.3%), and 10R (5.1%). N1 metastasis rates were generally higher across all lobes, especially at station 13. Notably, right lower lobe tumors exhibited high metastasis rates to the superior mediastinum. Survival analysis demonstrated a trend toward more favorable DFS among patients receiving systematic lymph node dissection (SLND) compared with those undergoing non-SLND (P = 0.182). Similarly, patients with ≥ 6 dissected lymph node stations showed a trend toward more favorable DFS compared with those with < 6 dissected lymph node stations (P = 0.100); however, neither association reached statistical significance. Furthermore, multivariable Cox regression identified non-adenocarcinoma histological types (squamous cell carcinoma: HR = 0.58, 95% CI: 0.37-0.92, P = 0.020; others: HR = 0.34, 95% CI: 0.17-0.70, P = 0.004) as independent predictors of improved DFS. For OS, advanced baseline clinical N stage (cN1 vs. cN0: HR = 8.48, 95% CI: 1.07-66.98, P = 0.043) was confirmed as an independent risk factor for worse survival, whereas non-adenocarcinoma/non-squamous histology (HR = 0.13, 95% CI: 0.02-0.95, P = 0.044) served as an independent protective factor.
conclusionsPost-NCIT lymph node involvement patterns in NSCLC patients varied according to primary tumor location. SLND and the retrieval of ≥ 6 dissected lymph node stations were associated with favorable DFS trends, although these findings were not statistically significant and require further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.